Lipids and CVD management: towards a global consensus
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Cardiovascular disease (CVD) is currently the leading cause of morbidity and mortality worldwide and its incidence is likely to increase. Multiple risk factors contribute to CVD. Elevated LDL-cholesterol (LDL-C) and triglyceride levels, low HDL-cholesterol levels, hypertension, type 2 diabetes, and smoking are key modifiable risk factors. Such risk factors are present in 80-90% of coronary heart disease (CHD) patients. For many factors, modification can significantly reduce CVD incidence. For example, statin-induced LDL-C reductions reduce cardiovascular events by 24-37% and smoking cessation reduces CHD mortality by 36%. The need to identify and treat these risk factors has led many national and local groups to develop clinical practice guidelines for management of CVD. Although the aim of such guidelines is to provide practitioners with a framework to identify, prioritize, and manage patients, the plethora of guidelines can cause confusion. In addition, research indicates that guidelines are not being optimally implemented. This review considers these practical issues, highlights the common goals shared by many guidelines, and focuses on how these can be best achieved. It also highlights areas where the guidelines differ and discusses points to consider when selecting the most appropriate recommendation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
De Backer, G. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00347-6 · Cited by 2,251
D'Agostino, R. B., Grundy, S., Sullivan, L. M., Wilson, P., & for the CHD Risk Prediction Group (2001) · JAMA · doi:10.1001/jama.286.2.180 · Cited by 2,108 · cited 1×
“The Framingham algorithm estimates risk accurately in European and American populations that have an average CHD risk similar to the Framingham cohort (a US population).(26) However, this algorithm over-estimates risk in populations with a lower baseline risk, such as those in France, Italy, and Spain.”
MethodThe Finnish Diabetes Prevention Study (DPS)
Lindström, J., Louheranta, A., Mannelin, M., Rastas, M., Salminen, V., Eriksson, J., Uusitupa, M., Tuomilehto, J., & for the Finnish Diabetes Prevention Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3230 · Cited by 1,848
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875 · cited 1×
“44 per 10 000 person-years of monotherapy with atorvastatin, pravastatin, or simvastatin.(40) Since statin monotherapy reduces CV risk by 35% in individuals at low or high risk,(41,42) patients with baseline 10 year risks of 5 and 20% have annual CVD risks of 0.”
Background
Cited by
Factores de riesgo cardiovascular. Perspectivas derivadas del Framingham Heart Study
O’Donnell, C. J., & Elosua, R. (2008) · Revista Española de Cardiología · doi:10.1157/13116658 · Cited by 266
Cardiovascular Risk Factors. Insights From Framingham Heart Study
O'Donnell, C. J., & Elosua, R. (2008) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(08)60118-8 · Cited by 265
Ferket, B. S. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.434 · Cited by 134
Apolipoproteins as markers and managers of coronary risk
Chan, D. C. (2006) · QJM · doi:10.1093/qjmed/hcl027 · Cited by 117
Small LDL-Cholesterol is Superior to LDL-Cholesterol for Determining Severe Coronary Atherosclerosis
Koba, S., Yokota, Y., Hirano, T., Ito, Y., Ban, Y., Tsunoda, F., Sato, T., Shoji, M., Suzuki, H., Geshi, E., et al. (2008) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e572 · Cited by 102
Metadata
- Authors
- Ballantyne, C., Arroll, B., & Shepherd, J.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-21
- Volume
- 26
- Issue
- 21
- Pages
- 2224-2231
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2038686786
- Cited by
- 87
- References
- 11
- FWCI
- 8.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipids and CVD management: towards a global consensus. https://app.cochat.ai/papers/10.1093/eurheartj/ehi373
- The paper
- Ballantyne, C., Arroll, B., & Shepherd, J. (2005). Lipids and CVD management: towards a global consensus. European Heart Journal. https://doi.org/10.1093/eurheartj/ehi373
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.